0001209191-21-005901.txt : 20210128 0001209191-21-005901.hdr.sgml : 20210128 20210128170835 ACCESSION NUMBER: 0001209191-21-005901 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210126 FILED AS OF DATE: 20210128 DATE AS OF CHANGE: 20210128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rhodes Jason P CENTRAL INDEX KEY: 0001577014 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 21566201 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-26 0 0001737953 Replimune Group, Inc. REPL 0001577014 Rhodes Jason P 18 COMMERCE WAY WOBURN MA 01801 1 0 0 0 Common Stock 2021-01-26 4 S 0 5558 46.14 D 946000 I See footnote Common Stock 2263627 I See footnote Common Stock 19285 I See footnote Shares were sold pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.95 to $46.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The shares are held directly by AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any. /s/ Ommer Chohan, Attorney-in-Fact 2021-01-28